Vaxcyte (PCVX) Asset Writedowns and Impairment (2022)

Vaxcyte's (PCVX) quarterly Asset Writedowns and Impairment came in at -$13000.0 in Q4 2022, down 108.33% on a QoQ basis from $156000.0 in Q2 2022.

Vaxcyte (PCVX) Asset Writedowns and Impairment (2022) Analysis & Trends

Vaxcyte (PCVX) has 1 years of Asset Writedowns and Impairment data on file, last reported at -$13000.0 in Q4 2022.

On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to -$13000.0 in Q4 2022; TTM through Sep 2023 was -$13000.0, a 106.1% decrease from a year earlier, with the FY2022 full-year figure at $200000.0, changed N/A from the prior year.
Asset Writedowns and Impairment for Q4 2022 stood at -$13000.0, down from $156000.0 in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for PCVX reached as high as $156000.0 in Q2 2022 and fell as low as -$13000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Vaxcyte	7.76 Bn	7.76 Bn	-

Download Data